HRQOL improvements in anemic CKD patients treated with darbepoetin alfa (Aranesp™)

被引：0

作者：

Ruhman, SN

Heifner, KJ

Fadem, SZ

Melvor, ME

Brenner, RM

Powers, KM

Ford, JM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] St Petersburg Heart Ctr, St Petersburg, FL USA

[3] Huston Kidney Ctr, Houston, TX USA

[4] Renal Associates, Little Rock, AR USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2002年 / 39卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A27 / A27

页数：1

共 50 条

[31] Epoetin alfa and darbepoetin alfa dosing patterns in anemic pre-dialysis chronic kidney disease patients
Mody, S
Padmanabhan, V
McKenzie, RS
Bookhart, B
VALUE IN HEALTH, 2006, 9 (03) : A96 - A96
[32] Aranesp® (darbepoetin alfa) administered every other week (Q2W) corrects and maintains hemoglobin (Hb) in chronic kidney disease (CKD) patients
Hertel, J
Locay, H
Scarlata, D
Prathikanti, R
Audhya, P
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A31 - A31
[33] Disease progression and long-term survival in anemic cancer patients undergoing chemotherapy are comparable in patients treated with darbepoetin alfa and placebo
Hedenus, Michael
Rossi, Greg
Dahlberg, Steve
Vansteenkiste, Johan
ANNALS OF ONCOLOGY, 2004, 15 : 223 - 223
[34] Aranesp™ (darbepoetin alfa) administered once every other week treats anemia in patients with chronic kidney disease (CKD) not receiving renal replacement therapy.
Toto, RD
Navarro, J
Roger, S
Churchill, DN
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 635A - 635A
[35] Intravenous Aranesp® (Darbepoetin Alfa) in the management of anaemia of haemodialysis patients previously receiving subcutaneous erythropoietin (rHuEPO).
Jenkins, KJ
Bennett, LI
Monk, A
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 459A - 459A
[36] Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
Hayashi, Terumasa
Maruyama, Shoichi
Nangaku, Masaomi
Narita, Ichiei
Hirakata, Hideki
Tanabe, Kenichiro
Morita, Satoshi
Tsubakihara, Yoshiharu
Imai, Enyu
Akizawa, Tadao
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (05): : 608 - 615
[37] Development of a strategy to successfully convert an ambulatory infusion center from procrit (epoetin alfa) to aranesp (darbepoetin alfa).
Longfield, V
Gebhart, B
Hayward, L
ONCOLOGY NURSING FORUM, 2005, 32 (02) : 470 - 470
[38] Once-monthly Aranesp® (darbepoetin alfa) maintains hemoglobin in elderly chronic kidney disease patients.
Ling, BN
Agarwal, A
Scarlata, D
Brenner, R
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S24 - S25
[39] Novel erythropoiesis stimulating protein -: NESP -: Darbepoetin alfa -: ARANESP® -: Hematopoietic -: Antianemic -: Oncolytic
不详
DRUGS OF THE FUTURE, 2001, 26 (03) : 304 - 305
[40] An extended terminal half-life for Aranesp® (darbepoetin alfa):: Results from a single-dose pharmacokinetic (PK) study in patients with chronic kidney disease (CKD)
Padhi, D
Jang, G
Smith, B
Marbury, T
Cooke, B
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255

← 1 2 3 4 5 →